GLRX and pulmonary fibrosis: While there have not been clinical trials testing Glrx as a therapeutic agent in CVD, advances in biological technologies such as gene therapy [132] and gene editing (e.g., CRISPR) [133], as well clinical Glrx administration as therapy for lung fibrosis [18], indicate potential going forward [134].